



CPS / Immunology Version 5 June 2020

Elecsys Troponin T hs: non reproducible elevated results with certain lots

Product Name	Elecsys Troponin T hs			
System	cobas e 801			
GMMI / Part No Device Identifier	Elecsys Troponin T hs (cobas e 801, 300 tests) - 08469873 190 Elecsys Troponin T hs (cobas e 801, 300 tests) - 07028075 190			
Production Identifier (Product name/Product code)	08469873 190: 419260, 436777, <mark>(not affected: 474941)</mark> 07028075 190: 429178, 460113, <mark>(not affected: 470034)</mark>			
SW Version	n/a			
Type of Action	Field Safety Corrective Action			

Dear Valued Customer,

Description of Situation

As described in the version 1 and 2 of the FSN-CPS-2019-022, the lots 419260, 436777 of Elecsys Troponin T hs (08469873 190) and lot 429178 of Elecsys Troponin T hs (07028075 190) showed in internal investigations and customer complaints an increased rate of non-reproducible elevated results.

The issue appears as follows:

Either result of multiple determinations is non-reproducible elevated compared to the other results of the same sample aliquot.

The issue has been observed with both plasma and serum samples.

It was confirmed that Troponin T hs (08469717 190 and 05092744 190) and Troponin T hs STAT (08469814 190 and 05092728 190) running on **cobas e** 411/**e** 601/**e** 602 do not show an increased rate of non-reproducible elevated results and can be considered not impacted by the issue.

The issue can lead to non-reproducible elevated Troponin T hs results and therefore may affect clinical interpretation.

With version 3 of this FSN it was communicated that the reagent (07028075 190) lot 460113 should be used with the same restrictions as the affected lots until additional data is obtained. Recent data suggest that for the lot 460113 observed high flyers were less pronounced and occurred with lower frequency compared to other affected lots. Nevertheless, the lot 460113 is considered affected by the issue and therefore respective restrictions will remain in place.



Investigation results suggest that distinction between affected and unaffected reagent lots is possible after maturation period of 14 weeks after reagent filling.

With version 4 of this SBN, we advised to use reagent (08469873 190) lot 474941 and reagent (07028075 190) lot 470034 with the restrictions. Both reagent lots were released before 14 weeks after reagent filling were reached and the advice was put in place as a precautionary measure.

In the meantime, the data obtained 14 weeks after reagent filling is available. Both reagent (08469873 190) lot 474941 and reagent (07028075 190) lot 470034 are inconspicuous and can therefore be used without restrictions.

Unique root cause/source of (para-)magnetic particles was not identified yet. A multifactorial background is assumed. However, multiple countermeasures to prevent contamination with (para-)magnetic particles are implemented on the basis of the risk analysis of the filing process. Furthermore, an additional QC release criteria has been defined and put in place to assess if a production lot is affected by an increased high-flyer frequency or not.

Customers must be informed regarding the updated workaround using the FSN-CPS-2019-022 version 5.

Actions to be taken by Roche Diagnostics

Immediate corrections were already taken and countermeasures to prevent contamination with (para-)magnetic particles were implemented based on the risk analysis of filling process. Upcoming lots will undergo extensive quality control measurements and if passed, will be released without restrictions.

Similar issue was observed with two lots of Elecsys CA 19-9 on cobas e 801 (reference to SBN-CPS-2020-001 version 2). At this point, there is no indication that further Elecsys assays (beyond Troponin T hs and CA 19-9) are affected by this issue.

Actions to be taken by the customer/user

Troponin T hs (08469717 190 and 05092744 190) and Troponin T hs STAT (08469814 190 and 05092728190) running on **cobas e** 411/601/602 can be used without restrictions. As a result, double determinations per sample are not necessary.

Elecsys Troponin T hs (08469873 190) lots 419260 and 436777 and Elecsys Troponin T hs (07028075 190) lots 429178 and 460113 running on **cobas e** 801 are affected. Please note that lot 419260 can be used again if not yet being discarded based on the advice in the version 1 of this SBN-CPS-2019-022.

Reagent (08469873 190) lot 474941 and reagent (07028075 190) lot 470034 are - based on the results of the quality control measurements - considered non affected and can therefore be used without restrictions. To enable the use of 300 determinations for those lots, new e- files (REC files) will be released (for technical details, refer to Q&A).

Customers using affected lots are asked to switch Elecsys Troponin T-hs from **cobas e** 801 to **cobas e** 411/ 601/602. In case this is not possible, customers using affected lots on **cobas e** 801 are advised to perform the following actions:

- 1. In order to reduce the frequency of non-reproducible elevated results, please ensure not to invert or shake the ePacks prior to loading to the analyzer and discard each ePack of the affected lots after the first 200 determinations (for technical details, refer to Q&A).
- 2. Perform double determinations from the same tube for all results ≥ 14ng/L in order to increase the detectability of possible non-reproducible elevated results (highflyers)*.
- Customers using algorithms for accelerated rule-in and rule-out decisions (e.g. the 0h/1h algorithm according to the 2015 ESC NSTEMI Guideline) are advised to perform double determinations for all results*.



*Important: Delays due to double determination can be reduced to a very minimum when ordering the two TnT hs applications (TnT hs ACN 10011 and TnT hs STAT ACN 10012) on **cobas e** 801 for two simultaneous measurements per sample.

If discrepant results are observed within a repetition, check the sample quality and if necessary re-centrifuge samples before a third measurement and contact your local point of contact at Roche Diagnostics to report the discrepant result.

This advice is valid until further notice.

For better overview of current reagents lots, please see table 1.

Taking into account the typical indications for the determination of cardiac troponins and the half-life, and kinetic of Troponin, no specific recommendations with respect to timeline of patient review and follow up are given. Any specific questions raised by the users should be addressed individually, considering all relevant clinical information.

The contamination of several Troponin T hs assay lots with (para)magnetic particles is only one of the known causes of non-reproducible results. Although corrections have been made to prevent the contamination, other causes may still lead to a sporadic occurrence of non-reproducible results in the future.

General reminder regarding occurrence of high flyers:

Some of the most important aspects are:


- Correct and good sample preanalytic according to the specifications of the respective primary tube manufacturer (e.g. centrifugation time, speed, temperature)
- Avoidance or complete elimination of foam on or clots in the samples
- Regular and complete equipment maintenance according to the manufacturer's specifications
- Regular visual checks of e.g. the sample carriers to ensure correct positioning of the tubes on the analyzers.
- •

Further details can be found in QN-CPS-2016-128.

<u>Due to these alternative causes, flyers may continue to appear in the future at the frequency typical of the laboratory before the product problem.</u>

Table 1

Product number	Description	Instrument	Lot numbers	Recommendation		
Elecsys® Troponin T hs with increased biotin tolerance						
08469873 190	Troponin T hs 300 tests	cobas e 801	396685	Use as usual		



- Customer using algorithms for accelerating rule-in & rule-out approach (0/1-h algorithm of the ESC 2015 guidelines for NSTEMI) are advised to perform double determinations regardless of the initial results.
- 2. As soon as new e-files (REC files) is available

Communication of this Field Safety Notice (if appropriate)

This notice must be passed on to all those who need to be aware within your organization where the devices have been distributed/supplied. (If appropriate).

Please transfer this notice to other organizations/individuals on which this action has an impact.

Please maintain awareness of this notice and resulting action for an appropriate period to ensure the effectiveness of the corrective action.

The following statement is mandatory in FSNs for EEA countries but is not required for the rest of the World:

Urgent Field Safety Notice | Immunology| FSN-CPS-2019-022 | Version 5





Include if applicable: The undersigned confirms that this notice has been notified to the appropriate Regulatory Agency.

We apologize for any inconvenience this may cause and hope for your understanding and your support.

<closing salutations>,

Contact Details

To be completed locally: Name Title Company Name Address Tel. +xx-xxx-xxxx xxxx

Email name@roche.com

Urgent Field Safety Notice | Immunology| FSN-CPS-2019-022 | Version 5